Sitimagene ceradenovec

Drug Profile

Sitimagene ceradenovec

Alternative Names: Cerepro; EG009

Latest Information Update: 16 Mar 2011

Price : $50

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 05 May 2010 Sitimagene ceradenovec is available for licensing worldwide (
  • 05 Jan 2010 Ark Therapeutics files formal request with the EMEA for re-examination of MAA for sitimagene ceradenovec in operable malignant Glioma
  • 18 Dec 2009 CHMP adopts negative opinion of sitimagene ceradenovec in operable malignant Glioma in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top